This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

Our Compounds

Boehringer Ingelheim is taking on cancer through a dedicated commitment to delivering first-in-class cancer cell-directed therapies, innovative immuno-oncology strategies and smart combination approaches.

Download a PDF of our compounds
Filter by:
Focus Area
Development stage
Target
Compound and target LATEST DEVELOPMENT PHASE
Phase I Phase II Phase III Approved
Cancer cell-directed and immuno-oncology therapies

Afatinib

  • EGFR (ErbB1); HER2 (ErbB2); ErbB3; ErbB4
    		•
    NSCLC
    A Approved

    Nintedanib

  • VEGFR; FGFR; PDGFR
    		•
    NSCLC
    A Approved

    Xentuzumab (BI 836845)

  • IGF ligands (IGF1; IGF2)
    		•
    NSCLC
    1 Phase I
    Breast cancer
    1 Phase I
    Breast cancer
    2 Phase II

    PD-1 inhibitor (BI 754091)
    Solid tumours
    1 Phase I

    LAG-3 inhibitor (BI 754111)
    Solid tumours
    1 Phase I

    VEGF/Ang2 inhibitor (BI 836880)
    Solid tumours
    1 Phase I

    BET inhibitor (BI 894999)
    Solid tumours
    1 Phase I

    SMAC mimetic (BI 891065)
    Solid tumours
    1 Phase I

    MDM2-p53 antagonist (BI 907828)
    Solid tumours
    1 Phase I

    SIRPα antagonist (BI 765063)
    Solid tumours
    1 Phase I

    LRP5/6 antagonist (BI 905677)
    Solid tumours
    1 Phase I

    mRNA-based cancer vaccine (BI 1361849)
    NSCLC
    1 Phase I

    SOS1::KRAS inhibitor (BI 1701963)
    Solid tumours
    1 Phase I

    ATP128 cancer vaccine
    Metastatic colorectal cancer
    1 Phase I

    STING agonist (in preparation)

    TRAILR2/CDH17 antibody (in preparation)

    DLL3-CD3 bispecific antibody (in preparation)

    CD73 inhibitor (in preparation)

    VSV-GP oncolytic virus platform (in preparation)

    MEK inhibitor (in preparation)
    Combination Approaches

    LAG-3 inhibitor (BI 754111)
    + PD-1 inhibitor (BI 754091)
    Solid tumours
    1 Phase I
    Solid tumours
    2 Phase II

    VEGF/Ang2 inhibitor (BI 836880)
    + PD-1 inhibitor (BI 754091)
    NSCLC
    1 Phase I

    SMAC mimetic (BI 891065)
    + PD-1 inhibitor

    Solid tumours
    1 Phase I

    MDM2-p53 antagonist (BI 907828)
    + LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)
    Solid tumours
    1 Phase I

    SIRPα myeloid checkpoint inhibitor (BI 765063)
    + PD-1 inhibitor (BI 754091)
    Solid tumours
    1 Phase I

    ATP128 cancer vaccine + PD-1 inhibitor (BI 754091)
    Metastatic colorectal cancer
    1 Phase I

    STING agonist (in preparation) + PD-1 inhibitor (BI 754091)
    Download a PDF of our compounds
    Back to top

    *Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information..

    **Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here.

     

    Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063, BI 1361849, SOS1::KRAS inhibitor, STING agonist and TRAILR2/CDH17 antibody are investigational compounds and have not been approved. Their safety and efficacy have not been established.

     

    Ang2, angiopoietin 2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; KRAS, Kirsten rat sarcoma; LAG-3, lymphocyte activation gene 3 protein; LRP5/6, lipoprotein receptor-related protein 5/6; MDM2, murine double minute 2 protein; mRNA, messenger ribonucleic acid; NSCLC: non-small-cell lung carcinoma; PD-1, programmed cell death protein-1; PDGFR, platelet-derived growth factor receptor; SIRPα, signal-regulatory protein alpha; SMAC, second mitochondria-derived activator of caspase; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

     

    © 2019 Boehringer Ingelheim International GmbH. All rights reserved.

    Page last updated: October 2019

    References

    1

    Prescribing Information: GIOTRIF®. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf (Accessed: October 2019).

    2

    Prescribing Information: VARGATEF®. https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed: October 2019).

    3

    ClinicalTrials.gov. NCT03099174. https://clinicaltrials.gov/ct2/show/NCT03099174 (Accessed: October 2019).

    4

    ClinicalTrials.gov. NCT02123823. https://clinicaltrials.gov/ct2/show/NCT02123823 (Accessed: October 2019).

    5

    ClinicalTrials.gov. NCT03659136. https://clinicaltrials.gov/ct2/show/NCT03659136 (Accessed: October 2019).

    6

    ClinicalTrials.gov. NCT03207191. https://clinicaltrials.gov/ct2/show/NCT03207191 (Accessed: October 2019).

    7

    ClinicalTrials.gov. NCT02632721. https://clinicaltrials.gov/ct2/show/NCT02632721 (Accessed: October 2019).

    8

    ClinicalTrials.gov. NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998 (Accessed: October 2019).

    9

    ClinicalTrials.gov. NCT03468426. https://clinicaltrials.gov/ct2/show/NCT03468426 (Accessed: October 2019).

    10

    ClinicalTrials.gov. NCT02952248. https://clinicaltrials.gov/ct2/show/NCT02952248 (Accessed: October 2019).

    11

    ClinicalTrials.gov. NCT03156114. https://clinicaltrials.gov/ct2/show/NCT03156114 (Accessed: October 2019).

    12

    ClinicalTrials.gov. NCT03780725. https://clinicaltrials.gov/ct2/show/NCT03780725 (Accessed: October 2019).

    13

    ClinicalTrials.gov. NCT03433898. https://clinicaltrials.gov/ct2/show/NCT03433898 (Accessed: October 2019).

    14

    ClinicalTrials.gov. NCT03166631. https://clinicaltrials.gov/ct2/show/NCT03166631 (Accessed: October 2019).

    15

    ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/ct2/show/NCT03697304 (Accessed: October 2019).

    16

    ClinicalTrials.gov. NCT02674152. https://clinicaltrials.gov/ct2/show/NCT02674152 (Accessed: October 2019).

    17

    ClinicalTrials.gov. NCT02689505. https://clinicaltrials.gov/ct2/show/NCT02689505 (Accessed: October 2019).

    18

    ClinicalTrials.gov. NCT02516553. https://clinicaltrials.gov/ct2/show/NCT02516553 (Accessed: October 2019).

    19

    ClinicalTrials.gov. NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381 (Accessed: October 2019).

    20

    ClinicalTrials.gov. NCT03604445. https://clinicaltrials.gov/ct2/show/NCT03604445 (Accessed: October 2019).

    21

    ClinicalTrials.gov. NCT04111458. https://clinicaltrials.gov/ct2/show/NCT04111458 (Accessed: October 2019).

    22

    ClinicalTrials.gov. NCT03164772. https://clinicaltrials.gov/ct2/show/NCT03164772 (Accessed: October 2019).

    23

    Boehringer Ingelheim. Data on file.

    24

    Boehringer Ingelheim. Data on file.